Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 7 York Road, Parktown 2193, South Africa; Department of Pharmaceutics, SET's College of Pharmacy, Dharwad 580 002, Karnataka, India.
Department of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.
Int J Biol Macromol. 2024 Apr;264(Pt 2):130645. doi: 10.1016/j.ijbiomac.2024.130645. Epub 2024 Mar 7.
Hyaluronic acid (HA), a biodegradable, biocompatible and non-immunogenic therapeutic polymer is a key component of the cartilage extracellular matrix (ECM) and has been widely used to manage two major types of arthritis, osteoarthritis (OA) and rheumatoid arthritis (RA). OA joints are characterized by lower concentrations of depolymerized (low molecular weight) HA, resulting in reduced physiological viscoelasticity, while in RA, the associated immune cells are over-expressed with various cell surface receptors such as CD44. Due to HA's inherent viscoelastic property and its ability to target CD44, there has been a surge of interest in developing HA-based systems to deliver various bioactives (drugs and biologics) and manage arthritis. Considering therapeutic benefits of HA in arthritis management and potential advantages of novel delivery systems, bioactive delivery through HA-based systems is beginning to display improved outcomes over bioactive only treatment. The benefits include enhanced bioactive uptake due to receptor-mediated targeting, prolonged retention of bioactives in the synovium, reduced expressions of proinflammatory mediators, enhanced cartilage regeneration, reduced drug toxicity due to sustained release, and improved and cost-effective treatment. This review provides an underlying rationale to prepare and use HA-based bioactive delivery systems for arthritis applications. With special emphasis given to preclinical/clinical results, this article reviews various bioactive-loaded HA-based particulate carriers (organic and inorganic), gels, scaffolds and polymer-drug conjugates that have been reported to treat and manage OA and RA. Furthermore, the review identifies several key challenges and provides valuable suggestions to address them. Various developments, strategies and suggestions described in this review may guide the formulation scientists to optimize HA-based bioactive delivery systems as an effective approach to manage and treat arthritis effectively.
透明质酸(HA)是一种可生物降解、生物相容且非免疫原性的治疗性聚合物,是软骨细胞外基质(ECM)的关键组成部分,已广泛用于治疗两种主要类型的关节炎,骨关节炎(OA)和类风湿性关节炎(RA)。OA 关节的特征是低浓度的解聚(低分子量)HA,导致生理粘弹性降低,而在 RA 中,相关免疫细胞过度表达各种细胞表面受体,如 CD44。由于 HA 固有的粘弹性及其靶向 CD44 的能力,人们对开发基于 HA 的系统以递送各种生物活性物质(药物和生物制剂)并治疗关节炎产生了浓厚的兴趣。考虑到 HA 在关节炎管理中的治疗益处和新型递送系统的潜在优势,通过基于 HA 的系统递送生物活性物质开始显示出优于仅生物活性物质治疗的改善结果。其益处包括由于受体介导的靶向作用而增强的生物活性摄取、生物活性物质在滑膜中的保留时间延长、促炎介质表达减少、软骨再生增强、由于持续释放而降低药物毒性以及改善和具有成本效益的治疗。本文提供了一个基本原理,用于制备和使用基于 HA 的生物活性递送系统来治疗关节炎。本文特别强调了临床前/临床结果,综述了各种负载生物活性物质的基于 HA 的颗粒载体(有机和无机)、凝胶、支架和聚合物-药物偶联物,这些载体已被报道用于治疗和管理 OA 和 RA。此外,本文还确定了几个关键挑战,并提供了有价值的建议来解决这些挑战。本文中描述的各种发展、策略和建议可能会指导制剂科学家优化基于 HA 的生物活性递送系统,作为有效治疗和管理关节炎的方法。